Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; lactose monohydrate; microcrystalline cellulose; magnesium stearate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: silica dimethyl silylate; magnesium stearate; microcrystalline cellulose; lactose monohydrate - perindopril generichealth tablets are indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that perindopril generichealth tablets be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; silica dimethyl silylate; microcrystalline cellulose; magnesium stearate - indopril 8 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 8 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; silica dimethyl silylate; lactose monohydrate - indopril 4 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 4 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; silica dimethyl silylate - indopril 2 is indicated for: the treatment of hypertension.the treatment of heart failure. in such patients it is recommended that indopril 2 be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril tablets have not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - sildenafil citrate, quantity: 28.09 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin - revatio is used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of revatio has not been evaluated in patients currently on bosentan therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate; hypromellose; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; calcium hydrogen phosphate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - moxifloxacin hcl eqv moxifloxacin - tablet, film coated - 400 mg - moxifloxacin hcl eqv moxifloxacin 400 mg